Related Experiment Video
Updated: Mar 13, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
18.8K
Experience with botulinum toxin in chronic migraine
A Castrillo Sanz1, N Morollón Sánchez-Mateos1, C Simonet Hernández1
1Sección de Neurología, Complejo Hospitalario de Segovia, Segovia, España.
Neurologia
|October 26, 2016
Summary
OnabotulinumtoxinA (OnabotA) significantly reduces headache days and pain intensity for chronic migraine patients over 16 months. Early treatment with OnabotA offers greater benefits for refractory cases.
Area of Science:
- Neurology
- Pharmacology
Background:
- Chronic migraine (CM) poses a significant challenge, impacting quality of life.
- OnabotulinumtoxinA (OnabotA) is an established treatment for CM.
Purpose of the Study:
- To evaluate the 16-month experience with OnabotA for CM in Segovia, Spain.
- To assess the benefits of OnabotA treatment, including headache frequency and pain intensity.
- To identify clinical markers predictive of a positive response to OnabotA therapy.
Main Methods:
- Prospective study involving 69 patients diagnosed with CM.
- OnabotA treatment administered over 16 months.
- Statistical analysis using two-way ANOVA and linear regression to assess effectiveness and identify response markers.
Main Results:
- Significant reduction in headache days and pain intensity observed (P < .005).
- Treatment benefits were sustained throughout the 16-month study period.
- A negative correlation was found between pain intensity reduction and prior treatment history.
Conclusions:
- OnabotA demonstrates sustained efficacy and safety in managing chronic migraine over time.
- Early initiation of OnabotA for refractory CM is recommended to maximize therapeutic benefits.
- OnabotA is a safe and well-tolerated option for long-term CM management.
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.3K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.3K
01:31Skeletal Muscle Relaxants: Therapeutic Uses
1.1K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.1K
01:20Myasthenia Gravis: Overview and Treatment
3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
01:26Cholinergic Antagonists: Therapeutic Uses
1.6K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.6K
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
4.8K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
4.8K
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
1.1K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
1.1K